Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3CNS 3Sarcoma 2Plasma cell 2Myeloid 2Dermatologic 2Classical hematology 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 166Rituximab 153Specimen Handling 111Biopsy 89Magnetic Resonance Spectroscopy 87Vincristine 85Doxorubicin 79Prednisone 78fludarabine 68venetoclax 65obinutuzumab 60ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 39blinatumomab 38Bendamustine Hydrochloride 34fludarabine phosphate 33prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 27Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vorinostat × Lymphoid × 90 days × Clear all
NCT05848687 2026-06-03

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Stanford University

Phase 1/2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02943642 2026-05-18

Resimmune®

Virogen Biotechnology Inc.

Phase 2 Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00336063 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡